Clinical Trial Update: A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 pediatric safety trial evaluating paricalcitol capsules in children aged 10 to 16 with Stage 5 chronic kidney disease on dialysis; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: End-Stage Renal Disease, Secondary Hyperparathyroidism | Phase 3 | Status: COMPLETED | Results posted: 2016-11-21